Thursday, July 29, 2021

Bayer Provides Update on Path to Closure of Roundup™ Litigation

Explore Your Topic

August 05, 2021

Investor Conference Call

Q2 2021 Results

US FDA Fast Track Designation for Clinical Candidate to Treat Parkinson’s Disease

Heart and Kidneys

Five Reasons to Care About the Risks of Chronic Kidney Disease

Calendar

August 05, 2021

2021 Half-Year Report

August 05, 2021

Q2 2021 Investor Conference Call

OVERVIEW

Megatrends Changing the Future

Can we solve the unsolvable?

Severe Droughts Require Action to Avoid a Food Crisis

Inclusion & Diversity

Bayer Strives for Gender Parity in All Management Levels by 2030

Uses and Safety Record

Let’s Talk About Glyphosate

Inform Yourself on Special Topics

Our Contribution to Fighting the COVID-19 Pandemic

Information for Patients

The Benefits and Risks of Medicines

Relevant Positions

Modern Slavery Act Statement

Latest News

Share Price / Index

August 4, 2021 11:40 CEST

August 4, 2021 11:11 CEST

July 29, 2021

Bayer Provides Update on Path to Closure of Roundup™ Litigation

July 21, 2021

Not intended for U.S. and UK Media

Bayer’s new symptomatic chronic heart failure treatment Verquvo™ (vericiguat) approved in EU

July 09, 2021

Not intended for U.S. and UK Media

U.S. FDA approves finerenone for the treatment of patients with chronic kidney disease associated with type 2 diabetes

Advance Your Career

Why Bayer

Working at Bayer

Meet Our Employees

Job Search

Explore Our Businesses

We address some of the world's most pressing global challenges and continue to develop new solutions. The population is constantly growing and its age is increasing. That is why it needs better medicines and high-quality food in sufficient quantities. Learn more about it here.

Pharmaceuticals